Additional Cervical Cancer Screening May Be Linked to Preterm Delivery
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 25, 2023 -- Additional recommended cervical cancer screenings before birth may be tied to an increased risk for preterm delivery (PTD), according to a study published online July 21 in JAMA Health Forum.
Rebecca A. Bromley-Dulfano, from Harvard University Medical School in Boston, and colleagues ascertained the population-level association between the number of guideline-recommended cervical cancer screenings and downstream PTD risk among U.S. women aged 18 to 24 years in a cross-sectional study using a difference-in-differences approach. National Vital Statistics System data were obtained from women aged 18 to 24 years with a singleton, nulliparous birth in the United States between 1996 and 2018 (11,333,151 women). PTD and very preterm delivery (VPTD) were defined as delivery before 37 and 34 weeks of gestational age, respectively.
The researchers found that the mean number of guideline-recommended screenings was 2.4 by the time of childbirth. Overall, PTD occurred in 10.1 percent of births and VPTD occurred in 2.9 percent of births. One additional recommended screening was associated with a 0.073 percent increase in PTD risk, but no significant change in the risk for VPTD. The increase in PTD risk was higher for women with hypertension or diabetes than those without these comorbidities (0.26 versus 0.06 percent).
"This study may help inform future recommendations for screening practices by furthering our understanding of the trade-offs involved in terms of maternal and neonatal outcomes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.